AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Prevalence and Determinants of Subclinical Atherosclerosis in Systemic Lupus Erythematosus Patients Based on CSTAR Cohort

By Wu J, Li H, Tian Z

Background: Cardiovascular disease is a major cause of long-term morbidity in systemic lupus erythematosus (SLE), yet subclinical atherosclerosis (AS) remains incompletely characterized in Asian SLE populations. Integrative clinical and genetic profiling may improve vascular risk stratification by identifying disease-specific determinants of early vascular injury. Hypothesis: We hypothesized that subclinical AS is common in Chinese SLE patients without established cardiovascular disease and is associated with traditional risk factors as well as SLE-specific immune, treatment-related, and genetic determinants. Methods: We prospectively studied 819 adults with SLE consecutively enrolled from the CSTAR registry at Peking Union Medical College Hospital between 2022 and 2024. All patients underwent standardized carotid ultrasound. Subclinical AS was defined as carotid intima-media thickness >0.9 mm or carotid plaque in the absence of prior cardiovascular disease. Univariable and multivariable logistic regression and restricted cubic spline(RCS) analyses were used to identify associated factors. In 521 genotyped patients, rare variants with minor allele frequency <0.01 in East Asians were aggregated at the gene level using Fisher’s exact test, followed by Gene Ontology and KEGG enrichment analyses. Results: Subclinical AS was detected in 90 of 819 patients with SLE (11.0%). In univariable analyses, older age (OR, 1.08 per year; 95% CI, 1.06-1.10; P<0.001), hypertension (OR, 2.76; 95% CI, 1.59-4.66; P<0.001), longer SLE duration, higher SLICC Damage Index, anticardiolipin antibody(ACL) positivity, and cyclophosphamide(CYC) exposure were associated with subclinical AS. In multivariable analyses, age, residual cholesterol, CYC use, and ACL antibody positivity remained independently associated with subclinical AS. RCS analyses suggested nonlinear associations for age and residual cholesterol, while SLE duration and CYC exposure showed predominantly linear patterns. Rare variant aggregation identified 230 genes associated with AS status at P<0.05. Enrichment analysis implicated cytoskeletal regulation, Ras/Rap1 signaling, cytokine-receptor interaction, oxidative stress, and lipid metabolism. Conclusions: Subclinical AS represents a clinically relevant yet often underrecognized cardiovascular burden in SLE patients without established cardiovascular disease. Age, residual cholesterol, CYC exposure, and ACL antibody positivity were independently associated with subclinical AS, supporting vascular risk stratification incorporating nontraditional lipid metrics, immune-mediated risk factors, and treatment-related exposures. Exploratory rare variant analysis suggested potential contributions of vascular remodeling, inflammatory signaling, oxidative stress, and lipid metabolism to early atherosclerotic injury in SLE.

doi.org/10.1161/circ.154.suppl_1.9984Populations

AgingResearch.News